Thromb Haemost 1990; 63(03): 430-434
DOI: 10.1055/s-0038-1645060
Original Article
Schattauer GmbH Stuttgart

Blood Coagulation after Long Distance Running: Antithrombin III Prevents Fibrin Formation

Peter Bärtsch
The Thrombosis Research Laboratory, Inselspital, Bern, Switzerland
,
André Haeberli
The Thrombosis Research Laboratory, Inselspital, Bern, Switzerland
,
P Werner Straub
The Thrombosis Research Laboratory, Inselspital, Bern, Switzerland
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 10. Oktober 1989

Accepted after revision 19. Februar 1990

Publikationsdatum:
30. Juni 2018 (online)

Summary

Physical exercise causes shortening of activated partial thromboplastin time (aPTT) and euglobulin clot lysis time. To investigate whether this activation of coagulation and fibrinolysis leads to in vivo thrombin or plasmin action after long distance running, 19 well trained male runners (36-65 years) were examined 5 to 53 min after termination of a 100 km race and 5 days later after at least 1 day without physical exercise. Compared to the control examination aPTT was decreased (30.2 ± 2.8 vs 35.3 ± 3.0 sec) and the following parameters were increased after the race: betathromboglobulin (40 ± 16 vs 23 ± 7 ng/ml), thrombin-antithrombin III (TAT) complexes (5.5 ± 3.4 vs 2.3 ± 0.7 pg/1), the fibrin(ogen) degradation products fragment E (57 ± 15 vs 35 ± 7 ng/ml) and B(3 15-42 (8.5 ± 2.5 vs 6.5 ± 2.5 ng/ml) (all p values <0.001). Platelet count, platelet factor 4, fibrinoepetide A (FPA) and haematocrit did not change significantly. Increased TAT complexes and unchanged FPA suggest that the generated thrombin was fully inactivated by antithrombin III (AT III) and did therefore not give rise to fibrin formation. The small increase of fibrin(ogen) degradation products indicates a minor in vivo activity of the fibrinolytic system. This investigation demonstrates the importance of AT III in the regulation of haemostasis in activated blood coagulation.

 
  • References

  • 1 Andrew M, Carter C, O’Brodovich H, Heigenhauser G. Increases in factor VIII complex and fibrinolytic activity are dependent on exercise intensity. J Appl Physiol 1986; 60: 1917-22
  • 2 Vogt A, Hofmann V, Straub PW. Lack of fibrin formation in exercise-induced activation of coagulation. Am J Physiol 1979; 236: H577-9
  • 3 Marsh NA, Gaffney PJ. Exercise-induced fibrinolysis - fact or fiction?. Thromb Haemostas 1982; 48: 201-3
  • 4 Small M, Tweddel AC, Rankin AC, Lowe G DO, Prentice C RM, Forbes CD. Blood coagulation and platelet function following maximal exercise: Effects of beta-adrenoceptor blockade. Haemostasis 1984; 14: 262-8
  • 5 Gallino A, Haeberli A, Straub PW, Steinbrunn W, Turina M, Rothlin ME. Does exercise induced myocardial ischaemia cause enhanced platelet activation and fibrin formation in patients with stable angina and severe coronary artery disease. Eur Heart J 1987; 8: 734-7
  • 6 Bartsch P, Schmidt EK, Straub PW. Fibrinopeptide A after strenuous physical exercise at high altitude. J Appl Physiol 1982; 53: 40-3
  • 7 Rocker L, Drygas WK, Heyduck B. Blood platelet activation and increase in thrombin activity following a marathon race. Eur J Appl Physiol 1986; 55: 374-80
  • 8 Ferguson EW, Bernier LL, Banta GR, Yu-Yahiro J, Schoomaker EB. Effects of exercise and conditioning on clotting and fibrinolytic activity in men. J Appl Physiol 1987; 62: 1416-21
  • 9 Ferguson EW, Barr CF, Bernier LL. Fibrinogenolysis and fibrinolysis with strenuous exercise. J Appl Physiol 1979; 47: 1157-61
  • 10 Mandalaki T, Dessypris A, Louizou C, Panayotopoulou C, Dimi-triadou C. Marathon run III: effects on coagulation, fibrinolysis, platelet aggregation and serum cortisol levels. Thromb Haemostas 1980; 43: 49-52
  • 11 Mandalaki T, Dessypris A, Louizou C, Bossinakou I, Panay-otoupoulou C, Antonopoulou A. Marathon run I: effects on blood coagulation and fibrinolysis. Thromb Haemostas 1977; 37: 444-50
  • 12 Arnesen H, Akesson I, Strocmme SB, Refsum HE. Fibrin/fibrinogen degradation products (FDP) in urine and serum after prolonged heavy exercise. Scand J Haematol 1976; 16: 279-84
  • 13 Collen D, Semeraro N, Tricot JP, Vermylen J. Turnover of fibrinogen, plasminogen, and prothrombin during exercise in man. J Appl Physiol 1977; 42: 865-73
  • 14 Gurewich V, Lipinska I, Lipinski B. Exercise-induced fibrinolytic activity and its effect on the degradation of fibrinogen, fibrin and fibrin-like precipitates. Thromb Res 1974; 5: 647-56
  • 15 Staubli M, Roessler B. Then mean red cell volume in long distance runners. Eur J Appl Physiol 1986; 55: 49-53
  • 16 Bolton AE, Ludlam CA, Moore S, Pepper DS, Cash JD. Three approaches to the radioimmunoassay of human betathromboglobulin. Br J Haematol 1976; 33: 233-9
  • 17 Levine SP, Krentz LS. Development of a radioimmunoassay for human platelet factor 4. Thromb Res 1977; 11: 673-86
  • 18 Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin-antithromhin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemostas 1988; 59: 101-6
  • 19 Clauss A. Gcrinnungsphysiologische Schnellmcthode zur Bestimmung des Fibrinogens. Acta Hacmat 1957; 17: 237-46
  • 20 Koppert PW, Kuipers W, Hoegee-de Nobel B, Brommer EJ P, Koopman J, Nieuwenhuizcn W. A quantitative enzyme immunoassay for primary fibrinogenolysis products in plasma. Thromb Haemostas 1987; 57: 25-8
  • 21 Koppert PW, Hoegee-de-Nobel E, Nieuwenhuizen W. A monoclonal antibody-based enzyme immunoassay for fibrin degradation products in plasma. Thromb Haemostas 1988; 59: 310-5
  • 22 Grimaudo V, Hauert J, Bachmann F, Kruithof EK O. Diurnal variation of the fibrinolytic system. Thromb Haemostas 1988; 59: 495-9
  • 23 Nossel HL, Yudelman I, Canfield RE, Butler VP, Spanondis K, Wilner GD, Qureshi GD. Measurement of fibrinopeptide A in human blood. J Clin Invest 1974; 54: 43-53
  • 24 Kudryk B, Robinson D, Netr C, Hessel B, Blombck M, Blombck B. Measurement in human blood of fibrinogen/fibrin fragments containing the B-beta 15-42 sequence. Thromb Res 1982; 25: 277-91
  • 25 Gordon YB, Martin MJ, Landon J, Chard T. The development of radioimmunoassays for fibrinogen degradation products: fragments D and E. Br J Haematol 1975; 29: 109-19
  • 26 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54
  • 27 Alkjaersig N, Fletcher AP. Catabolism and excretion of fibrinopep-tide-A. Blood 1982; 60: 148-56
  • 28 Kaplan KL, Owen J. Plasma levels of betathromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood 1981; 57: 199-202
  • 29 Dimitriadou C, Dessypris A, Louizou C, Mandalaki T. Marathon run II: Effects on platelet aggregation. Thromb Haemostas 1977; 37: 451-5
  • 30 Watts EJ, Weir P. Reduced platelet aggregation in long-distance runners. Lancet 1989; I: 1013
  • 31 Marcella JJ, Nichols AB, Johnson LL, Owen J, Reison DS, Kaplan KL, Cannon PJ. Exercise-induced myocardial ischemia in patients with coronary artery disease: Lack of evidence for platelet activation or fibrin formation in peripheral venous blood. J Am Coll Cardiol 1983; 1: 1185-93
  • 32 Mant MJ, Kappagoda CT, Quinlan J. Lack of effect of exercise on platelet activation and platelet reactivity. J Appl Physiol 1984; 57: 1333-7
  • 33 Farrell PA, Gustafson AB, Morgan WP, Pert CB. Enkephalins, catecholamines, and psychological mood alterations: effects uf prolonged exercise. Med Sci Sports Exerc 1987; 19: 347-53
  • 34 Miller BJ, Pate RR, Burgess W. Foot impact force and intravascular hemolysis during distance running. Int J Sports Med 1988; 9: 56-60
  • 35 Mandalaki T, Dessypris A, Makris P, Louizou C, Dimitriadou C. Marathon run: Effect on antithrombin III. Thromb Haemostas 1978; 40: 196-7
  • 36 Hoek JA, Sturk A, Wouter ten Cate J, Lamping RJ, Berends F, Borm JJ J. Laboratory and clinical evaluation of an assay of thrombin-antithrombin III complexes in plasma. Clin Chem 1988; 34: 2058-62
  • 37 Jain SK. In vivo externalization of phosphatidylserine and phos-phatidylethanolamine in the membrane bilayer and hypercoagulability by the lipid peroxidation of erythrocytes in rats. J Clin Invest 1985; 76: 281-6
  • 38 Gallino A, Haeberli A, Baur HR, Straub PW. Fibrin formation and platelet aggregation in patients with severe coronary artery disease: relationship with the degree of myocardial ischemia. Circulation 1985; 72: 27-30
  • 39 Gallino A, Haeberli A, Straub PW. Fibrinopeptide A excretion in urine in patients with atherosclerotic artery disease. Thromb Res 1985; 38: 237-44
  • 40 Blanke H, Praetorius G, Leschke M, Seitz R, Egbring R, Strauer BE. Die Bedeutung des Thrombin-Antithrombin-III-Komplexes in der Diagnostik der Lungenembolie und der tiefen Venenthrombose -Vergleich mit Fibrinopeptid A, Plättchenfaktor 4 und Betathromboglobulin. Klin Wochenschr 1987; 65: 757-63
  • 41 Bauer KA, Rosenberg RD. Thrombin generation in acute promy-elocytic leukemia. Blood 1984; 64: 791-6
  • 42 Kobayashi T, Terao T. Preeclampsia as chronic disseminated intravascular coagulation. Gynecol Obstet Invest 1987; 24: 170-8
  • 43 Douglas JT, Shah M, Lowe GD O, Belch JJ F, Forbes CD, Prentice CR M. Plasma fibrinopeptide A and betathromboglobulin in pre-eclampsia and pregnancy hypertension. Thromb Haemostas 1982; 47: 54-5
  • 44 Hellgren M, Tengborn L, Abildgaard U. Pregnancy in women with congenital antithrombin III deficiency: experiences of treatment with heparin and antithrombin. Gynecol Obstet Invest 1982; 14: 127-41
  • 45 Urano T, Kamiya T, Sakaguchi S, Takada Y, Takada A. Fibrinogenolysis and fibrinolysis in normal volunteers and patients with thrombosis after infusion of uiukinase. Thromb Res 1985; 39: 145-55
  • 46 Marsh N, Gaffney P. Some observations on the release of extrinsic and intrinsic plasminogen activators during exercise in man. Haemostasis 1980; 9: 238-47